Idarubicin hydrochloride is a chemical compound that is used as a chemotherapeutic agent in the treatment of various types of cancer. It is a synthetic analog of the anthracycline antibiotic, daunorubicin, and is structurally similar to doxorubicin. Idarubicin hydrochloride has been studied extensively in preclinical and clinical trials and has shown promising results in the treatment of leukemia, lymphoma, and solid tumors. In this article, we will discuss the chemical name, molecular formula, formula weight, and CAS number of Idarubicin hydrochloride. We will also explore the health benefits, mechanism of action, potential effects, safety, side effects, and dosing information for this potent chemotherapeutic agent.
Chemical Name:
The chemical name of Idarubicin hydrochloride is 5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxyhydrochloride, (7S,9S)-.
Molecular Formula:
The molecular formula of Idarubicin hydrochloride is C26H27NO9·HCl.
Formula Weight:
The formula weight of Idarubicin hydrochloride is 533.96.
CAS No:
The CAS number for Idarubicin hydrochloride is 57852-57-0.
Top Ten Keywords from Google and Synonyms:
Health Benefits of Idarubicin Hydrochloride:
Idarubicin hydrochloride has shown potential therapeutic benefits in various preclinical and clinical studies. It is a potent chemotherapeutic agent that is structurally similar to doxorubicin and shares its mechanism of action in the inhibition of topoisomerase II. Topoisomerase II is an enzyme that is essential for DNA replication and cell division. Inhibition of topoisomerase II by Idarubicin hydrochloride leads to DNA damage and cell death in cancer cells. Idarubicin hydrochloride has been found to be effective in the treatment of acute myeloid leukemia, lymphoma, and solid tumors.
Potential Effects of Idarubicin Hydrochloride:
Several preclinical and clinical studies have demonstrated the potential therapeutic effects of Idarubicin hydrochloride. In preclinical studies, Idarubicin hydrochloride has been found to inhibit topoisomerase II, induce DNA damage and cell death in cancer cells. In clinical studies, Idarubicin hydrochloride has been found to be effective in the treatment of various types of cancer, including acute myeloid leukemia, small cell lung cancer, and lymphoma. Moreover, Idarubicin hydrochloride has shown a favorable pharmacokinetic profile, which may contribute to its anti-tumor activity.
Product Mechanism:
Idarubicin hydrochloride is a potent chemotherapeutic agent that acts by inhibiting topoisomerase II. Topoisomerase II is an enzyme that is essential for DNA replication and cell division. Inhibition of topoisomerase II by Idarubicin hydrochloride leads to DNA damage and cell death in cancer cells. Moreover, Idarubicin hydrochloride may also act as a free radical generator, which may contribute to its anti-tumor activity.
Safety:
Idarubicin hydrochloride has been found to be safe and well-tolerated in preclinical and clinical studies. However, like any other medication, Idarubicin hydrochloride can have potential side effects, which may include bone marrow suppression, cardiotoxicity, nausea, vomiting, and alopecia. Therefore, careful monitoring of hematologic parameters and cardiac function may be required during treatment with Idarubicin hydrochloride.
Side Effects:
The potential side effects of Idarubicin hydrochloride may include bone marrow suppression, cardiotoxicity, nausea, vomiting, and alopecia. Therefore, careful monitoring of hematologic parameters and cardiac function may be required during treatment with Idarubicin hydrochloride.
Dosing Information:
The optimal dosing of Idarubicin hydrochloride has not yet been established. However, in clinical trials, Idarubicin hydrochloride has been administered intravenously at doses ranging from 5 to 12 mg/m2/day for up to 3 days. The dosing schedules and regimens for Idarubicin hydrochloride may vary depending on the type of cancer being treated, the stage of the disease, and the patient's overall health and medical history.
Conclusion:
Idarubicin hydrochloride is a potent chemotherapeutic agent that has shown promising results in preclinical and clinical trials. It is a synthetic analog of the anthracycline antibiotic, daunorubicin, and is structurally similar to doxorubicin. Idarubicin hydrochloride acts by inhibiting topoisomerase II, which leads to DNA damage and cell death in cancer cells. It has been found to be effective in the treatment of acute myeloid leukemia, lymphoma, and solid tumors. Moreover, Idarubicin hydrochloride has shown a favorable pharmacokinetic profile, which may contribute to its anti-tumor activity. However, like any other medication, Idarubicin hydrochloride can have potential side effects, and careful monitoring of hematologic
